Methods for generating therapeutic delivery platforms

Patent metadata

Field	Value
Publication number	US-11162143-B2
Application number	US-202117236561-A
Country	US
Kind code	B2
Filing date	Apr 21, 2021
Priority date	Oct 21, 2018
Publication date	Nov 2, 2021
Grant date	Nov 2, 2021

Abstract

Methods for producing engineered exosomes and other vesicle-like biological targets, including allowing a target vesicle-like structure to react and bind with immunomagnetic particles; capturing the immunomagnetic particle/vesicle complex by applying a magnetic field; further engineering the captured vesicles by surface modifying with additional active moieties or internally loading with active agents; and releasing the engineered vesicle-like structures, such as by photolytically cleaving a linkage between the particle and engineered vesicle-like structures, thereby releasing intact vesicle-like structures which can act as delivery vehicles for therapeutic treatments.

First claim

The invention claimed is:

1. A method for capture and photorelease of extracellular vesicles from a test sample suspected of containing one or more target extracellular vesicles, comprising:
contacting said test sample with a plurality of immunomagnetic particles in a test container to create a first assay mixture, said immunomagnetic particles each comprising:
a central magnetic particle comprising a core particle having a surface; a graphene-oxide-layer coating said core particle, said graphene-oxide layer comprising graphene-oxide nanosheets, said graphene-oxide nanosheets being covalently bonded to the particle surface; and at least one polydopamine polymer coupled with the graphene-oxide nanosheets,
a targeting moiety coupled to the at least one polydopamine polymer, and
a photocleavable linker, said photocleavable linker connecting said magnetic particle and said targeting moiety,
wherein said target extracellular vesicles, if present, are bound by said targeting moiety to create an immunomagnetic complex;

magnetically immobilizing said immunomagnetic complexes at a first location in said container;
washing said first assay mixture and resuspending said magnetically immobilized immunomagnetic complexes in solution to create a second assay mixture;
exposing said immunomagnetic complexes to activating radiation to cleave said photocleavable linker, wherein said target extracellular vesicles are released from said immunomagnetic complex to yield released extracellular vesicles and released immunomagnetic particles;
magnetically immobilizing said released immunomagnetic particles at a second location in said container, wherein said released target extracellular vesicles remain suspended in the second assay mixture; and
isolating said released target extracellular vesicles from the second assay mixture, and optionally separately recovering said released immunomagnetic particles.

2. The method of claim 1 , wherein said test sample is selected from a biological fluid selected from the group consisting of cell culture medium, tissue fluid, urine, milk, saliva, serum, plasma, blood, cerebrospinal fluid, nasal secretions, exhaled breath condensate, tears, adipose tissue, seminal fluid, vaginal secretions, synovial fluid, pleural fluid (pleural lavage), pericardial fluid, peritoneal fluid, amniotic fluid, otic fluid, gastric fluid, placental fluid, breast milk, Perilymph fluid, ascitic fluid, and combinations thereof.

3. The method of claim 1 , wherein said first or second assay mixture comprises water or buffer system selected from the biological buffer consisting of, but not limited to, phosphate buffered saline, HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), MOPS, Bis-Tris, MOPSO, ADA, ACES, PIPES, BES, TES, MOBS, and mixtures thereof.

4. The method of claim 1 , wherein said assay volume ranges from 1 μL to 10 L.

5. The method of claim 1 , wherein said targeting moiety is selected from the group consisting of antibodies, aptamers, antigenic peptides, tissue targeting/penetration peptides, MEW binding peptides, neoantigens, phage displayed epitopes, nucleic acid oligos, enzyme, receptors, inhibitors, and combinations thereof.

6. The method of claim 1 , wherein the photocleavable linkage comprises biotin.

7. The method of claim 1 , wherein said test container is selected from the group consisting of microfluidics chambers, test tubes, centrifuge tubes, microtubes, beakers, vials, flasks, bottles, ELISA well plate, 6-well, 12-well, 24-well, 48-well, 96-well, or 384-well plates, and cell culture containers.

8. The method of claim 1 , wherein said immunomagnetic particles have a diameter of 5 nm or greater.

9. The method of claim 1 , further comprising detecting one or more biomarkers, or multi-omic analysis in said released target extracellular vesicles.

10. The method of claim 9 , further comprising rendering a diagnosis based upon said one or more biomarkers.

11. The method of claim 10 , wherein said diagnosis is a cancer diagnosis, wherein said method is repeated over time, said method further comprising monitoring the progression of said cancer over time.

12. The method of claim 10 , wherein said diagnosis is a cancer diagnosis, wherein said method is repeated after treatment for said diagnosis, said method further comprising monitoring the effect said treatment of said cancer.

13. The method of claim 9 , said assay having high sensitivity for said one or more biomarkers.

14. The method of claim 9 , wherein said biomarkers are selected from the group consisting of nucleic acids, proteins, peptides, enzymes, inhibitors, lipids, metabolites, cytokines, stimulating factors, hormones, fragments thereof, and mutated forms thereof.

15. The method of claim 10 , wherein said diagnosis is a specific genetic mutation, or expression level changes of a biomarker or downstream product thereof, such as mRNA, miRNA, proteins, and peptides.

16. The method of claim 1 , wherein said released target extracellular vesicles comprise a surface modified with one or more of said targeting moieties, said targeting moieties remaining bound to said target extracellular vesicles after said release.

17. The method of claim 16 , wherein said targeting moieties are active agents.

18. The method of claim 1 , wherein said container is a microfluidic mixing channel, wherein said magnetically immobilizing said immunomagnetic complexes at a first location comprises applying a magnetic field within a microfluidic chamber, and wherein after photolytically releasing said immunomagnetic particles and said target extracellular vesicles, said magnetically immobilizing said released immunomagnetic particles at a second location comprises immobilizing said released immunomagnetic particles in a microfluidic chamber, wherein said released target extracellular vesicles are washed downstream to an outlet of the microfluidic mixing channel.

19. A composition comprising a plurality of released target extracellular vesicles prepared according to claim 1 , wherein said released target extracellular vesicles each comprise a surface modified with one or more of said targeting moieties, said targeting moieties remaining bound to said target extracellular vesicles after said release, wherein said target extracellular vesicles remain intact after said release, wherein said targeting moieties are active agents.

20. The composition of claim 19 , wherein said active agents are therapeutic or diagnostic nucleic acids, drugs, small molecule compounds, chemotherapeutics, stimulating factors, binding peptides, and/or antigens.

21. A method of treatment or diagnosis comprising administering to a subject in need thereof, a composition according to claim 19 .

22. The method of claim 21 , wherein said targeting moieties are released from said target extracellular vesicles before administering said target extracellular vesicles to said subject.

23. A composition comprising a plurality of released target extracellular vesicles prepared according to claim 1 , wherein said released target extracellular vesicles each comprise a surface modified with one or more of said targeting moieties, said targeting moieties having been released from said target extracellular vesicles, wherein said target extracellular vesicles remain intact after said release.

Assignees

• Univ Kansas
• Univ Kansas State

Inventors

• He Mei

Classifications

• G01N33/575

  for cancer · CPC title

• G01N33/57585

  involving compounds identifiable in body fluids · CPC title

• B01L2200/0668

  Trapping microscopic beads · CPC title

• B01L2400/043

  magnetic forces · CPC title

• B01L2300/0819

  Microarrays; Biochips · CPC title